Quantitative proteomics suggests decrease in the secretogranin‐1 cerebrospinal fluid levels during the disease course of multiple sclerosis

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Proteomics

• Publication date

  2015-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/pmic.201400142PMID 26152395
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes.

  2015cited by this paper
• Cerebrospinal fluid proteomics in multiple sclerosis.

  2015cited by this paper
• Effects of Blood Contamination and the Rostro-Caudal Gradient on the Human Cerebrospinal Fluid Proteome

  2014cited by this paper
• The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review.

  2014cited by this paper
• In-depth Characterization of the Cerebrospinal Fluid (CSF) Proteome Displayed Through the CSF Proteome Resource (CSF-PR)*

  2014cited by this paper
• The role of chromogranin B in an animal model of multiple sclerosis.

  2013cited by this paper
• Western Blots versus Selected Reaction Monitoring Assays: Time to Turn the Tables?

  2013cited by this paper
• Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis

  2013cited by this paper
• Gray Matter Is Targeted in First-Attack Multiple Sclerosis

  2013cited by this paper
• Measuring and managing ratio compression for accurate iTRAQ/TMT quantification.

  2013cited by this paper
• Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM.

  2013cited by this paper
• Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics.

  2011cited by this paper
• Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies

  2011cited by this paper
• C-terminal Domain of Chromogranin B Regulates Intracellular Calcium Signaling*

  2011cited by this paper
• Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis.

  2010cited by this paper
• Addressing Accuracy and Precision Issues in iTRAQ Quantitation*

  2010cited by this paper
• A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking

  2009cited by this paper
• Pharmacological Treatment of Early Multiple Sclerosis

  2008cited by this paper
• Multiple sclerosis‐related proteins identified in cerebrospinal fluid by advanced mass spectrometry

  2008cited by this paper
• Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis

  2007cited by this paper
• Upregulation of calpain correlates with increased neurodegeneration in acute experimental auto‐immune encephalomyelitis

  2005cited by this paper
• Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

  2005cited by this paper
• Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger.

  2004cited by this paper
• Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics.

  2003cited by this paper
• mechanisms of disease The Chromogranin – Secretogranin Family

  2003cited by this paper
• The chromogranin-secretogranin family.

  2003cited by this paper
• Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis.

  2001cited by this paper
• Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

  2001cited by this paper
• Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

  2001cited by this paper
• Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

  2000cited by this paper
• PE-11, a peptide derived from chromogranin B, in the human brain.

  1999cited by this paper
• AXONAL TRANSECTION IN THE LESIONS OF MULTIPLE SCLEROSIS

  1998cited by this paper
• Axonal transection in the lesions of multiple sclerosis.

  1998cited by this paper
• Levels and proteolytic processing of chromogranin A and B and secretogranin II in cerebrospinal fluid in neurological diseases

  1998cited by this paper
• A prospective study on the predictive value of CSF oligoclonal bands and MRI in acute isolated neurological syndromes for subsequent progression to multiple sclerosis.

  1996cited by this paper
• The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study.

  1993cited by this paper
• Ionic mechanisms of anoxic injury in mammalian CNS white matter: role of Na+ channels and Na(+)-Ca2+ exchanger

  1992cited by this paper
• Chromogranins A, B, and C: Widespread Constituents of Secretory Vesicles a

  1987cited by this paper

• Quantitative proteomics and multi-omics analysis identifies potential biomarkers and the underlying pathological molecular networks in Chinese patients with multiple sclerosis

  2024cites this paper
• Immune profiling in multiple sclerosis: a single-center study of 65 cytokines, chemokines, and related molecules in cerebrospinal fluid and serum

  2023cites this paper
• Cancer Proteomics for Cellular Dysfunction: Insights and Trends.

  2023cites this paper
• Proteomics in Multiple Sclerosis: The Perspective of the Clinician

  2022cites this paper
• Proteomics and Its Role in Diagnosis of Auto Immune Diseases

  2022cites this paper
• Posttranslational modifications of proteins are key features in the identification of CSF biomarkers of multiple sclerosis

  2022cites this paper
• Multiomics Studies Investigating Recurrent Pregnancy Loss: An Effective Tool for Mechanism Exploration

  2022cites this paper
• FastCAT Accelerates Absolute Quantification of Proteins Using Multiple Short Nonpurified Chimeric Standards

  2021cites this paper
• Multiple Sclerosis Biomarker Discoveries by Proteomics and Metabolomics Approaches

  2021cites this paper
• Antibody and Protein Profiles in Glaucoma: Screening of Biomarkers and Identification of Signaling Pathways

  2021cites this paper
• Proteomic profile of vitreous in patients with tubercular uveitis.

  2020cites this paper
• Development of robust targeted proteomics assays for cerebrospinal fluid biomarkers in multiple sclerosis

  2020cites this paper
• Protein profiling of cerebrospinal fluid from patients undergoing vestibular schwannoma surgery and clinical significance.

  2019cites this paper
• Cerebrospinal fluid biomarkers link toxic astrogliosis and microglial activation to multiple sclerosis severity.

  2019cites this paper
• Fatigue in primary Sjögren’s syndrome: A proteomic pilot study of cerebrospinal fluid

  2019cites this paper
• Recent insights into Mycobacterium tuberculosis through proteomics and implications for the clinic

  2019cites this paper
• Proteomic Approaches to Decipher Mechanisms Underlying Pathogenesis in Multiple Sclerosis Patients

  2019cites this paper
• Proteomics Approaches Applied to Regenerative Medicine: Perspectives in Stem Cell Proteomics

  2019cites this paper
• Genomics, Proteomics, and Metabolomics for Stem Cells Monitoring in Regenerative Medicine

  2019cites this paper
• Ann C

  2019cites this paper
• Recent Trends in System-Scale Integrative Approaches for Discovering Protective Antigens Against Mycobacterial Pathogens

  2018cites this paper
• Proteomic study on neurite responses to oxidative stress: search for differentially expressed proteins in isolated neurites of N1E-115 cells

  2018cites this paper
• Proteomic-based Signature of Brain-related Proteins as Novel Candidate Biomarkers for Alzheimer’s Disease Diagnosis

  2018cites this paper
• Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia.

  2018cites this paper
• Targeted Mass Spectrometry-Based Assays for Relative Quantification of 30 Brain-Related Proteins and Their Clinical Applications.

  2018cites this paper
• Identification of candidate biomarkers in converting and non-converting clinically isolated syndrome by proteomics analysis of cerebrospinal fluid

  2018cites this paper
• Proteomics: Technologies and Their Applications.

  2017cites this paper
• In-Depth Cerebrospinal Fluid Quantitative Proteome and Deglycoproteome Analysis: Presenting a Comprehensive Picture of Pathways and Processes Affected by Multiple Sclerosis.

  2017cites this paper
• CD44 deletion leading to attenuation of experimental autoimmune encephalomyelitis results from alterations in gut microbiome in mice

  2017cites this paper
• A Urinary Metabolic Signature for Multiple Sclerosis and Neuromyelitis Optica.

  2016cites this paper
• Metabolomics in multiple sclerosis

  2016cites this paper
• Precision medicine in multiple sclerosis: biomarkers for diagnosis, prognosis, and treatment response.

  2016cites this paper
• CSF-PR 2.0: An Interactive Literature Guide to Quantitative Cerebrospinal Fluid Mass Spectrometry Data from Neurodegenerative Disorders*

  2016cites this paper
• Deciphering the biochemistry and identifying biomarkers to multiple sclerosis

  2015cites this paper
• Resuscitation Plus

  year unknowncites this paper